International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance provides recommendations to sponsors concerning clinical studies to assess the potential of a new drug to cause cardiac arrhythmias, focusing on the assessment of changes in the QT/QTc interval on the electrocardiogram as a predictor of risk. The guidance is intended to encourage the assessment of drug effects on the QT/QTc interval as a standard part of drug development and to encourage the early discussion of this assessment with FDA.
D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards*; D003226:Congresses as Topic; D004341:Drug Evaluation / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D005060:Europe; D017408:Guidelines as Topic; D006801:Humans; D007391:International Cooperation; D007564:Japan; D008133:Long QT Syndrome / Q000139:chemically induced*; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration